OBJECTIVE: To review the epidemiology, mycology, clinical features and diagnosis, current
pharmacotherapy, and pharmacoeconomics of onychomycosis. DATA SOURCES: We …

Since the 1950s there has been an increase in the incidence of invasive fungal disease. The
first successful systemically administered antifungal drug, amphotericin B, was introduced in …

Concurrent or sequential antifungal treatment for invasive mycoses has been typically
considered as an option to improve results of monotherapy. However, data on the efficacy of …

Five oral antifungal agents are available on the market today that have proved to be useful
in the typical dermatology practice: griseofulvin, ketoconazole, itraconazole, fluconazole …

Synergy between antifungal drugs is well recognized. However, combinations of antifungals
are yet to be widely adopted to treat onychomycosis. The rationale for the combination of …

Historical clinical observations suggested that cellular immunity is central in the outcome of
deep fungal infections, and experimental observations later proved this. Unstimulated …

Successful chemotherapy of the systemic mycoses now covers a span of more than 75 years
and dates to the first reported use of potassium iodide for treatment of sporotrichosis. The …

In a comprehensive mycosis fungoides program, 60 patients have been seen with a
pathologic diagnosis of this disease. Forty-four patients with advanced disease were …

The success rate of onychomycosis treatment is limited by several factors, including the
access of the therapeutic agent to the fungal mass, the presence of conidia, and the …

Opportunistic fungi are the most important pathogens in modern world. They are responsible
for severe infections in majority of immunocompromised patients. These microorganisms are …